BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
Phase 1
Completed
- Conditions
- Anemia
- Interventions
- Drug: BAY85-3934Drug: Placebo
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT01458028
Iloprost Therapy in Patients With Critical Limb Ischemia
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 126
- Registration Number
- NCT01458041
Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain
Phase 3
Completed
- Conditions
- Pharyngitis
- Interventions
- Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placeboDrug: Acetaminophen + placeboDrug: Placebo
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 177
- Registration Number
- NCT01453400
Study To Assess the Dietary Carbohydrate Content of Indian Diabetic Population
Completed
- Conditions
- Metabolic DiseaseDiabetes Mellitus
- Interventions
- Other: No drug
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 796
- Registration Number
- NCT01450592
Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
Completed
- Conditions
- Wet Macular Degeneration
- Interventions
- Drug: Anti-VEGF injections
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 480
- Registration Number
- NCT01448538
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2609
- Registration Number
- NCT01447043
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
Completed
- Conditions
- Arthroplasty, Replacement, KneeArthroplasty, Replacement, Hip
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2293
- Registration Number
- NCT01444586
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Phase 2
Completed
- Conditions
- Cardiovascular DiseaseCoronary Artery Disease
- Interventions
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 108
- Registration Number
- NCT01442792
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Oncology
- Interventions
- Drug: BAY94-9343Drug: BAY94-9343 (Expansion)Drug: BAY94-9343 (1.8 mg/kg)Drug: BAY94-9343 (2.2 mg/kg)
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 148
- Registration Number
- NCT01439152
Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
Completed
- Conditions
- Haemophilia A
- Interventions
- Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT01436825
Β© Copyright 2025. All Rights Reserved by MedPath